Article
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
Antimicrobial agents and chemotherapy - 1 Mar 2007
Tenney Daniel J, Rose Ronald E, Baldick Carl J, Levine Steven M, Pokornowski Kevin A, Walsh Ann W, Fang Jie, Yu Cheng-Fang, Zhang Sharon, Mazzucco Charles E, Eggers Betsy, Hsu Mayla, Plym Mary Jane, Poundstone Patricia, Yang Joanna, Colonno Richard J
Abstract excerpt
Entecavir (ETV) is a deoxyguanosine analog approved for use for the treatment of chronic infection with wild-type and lamivudine-resistant (LVDr) hepatitis B virus (HBV). In LVD-refractory patients, 1.0 mg ETV suppressed HBV DNA levels to below the level of detection by PCR (<300 copies/ml) in 21% and 34% of patients by Weeks 48 and 96, respectively. Prior studies showed that virologic rebound due to ETV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.